key: cord-0721061-kaekj7ic authors: Sisay, A.; Hartnack, S.; Tiruneh, A.; Desalegn, Y.; Tesfaye, A.; Desta, A. F. title: Evaluating diagnostic accuracies of Panbio™ COVID-19 rapid antigen test and RT-PCR for the detection of SARS-CoV-2 in Addis Ababa, Ethiopia using Bayesian Latent-Class Models (BLCM) date: 2022-04-28 journal: nan DOI: 10.1101/2022.04.25.22274285 sha: 7373581b081f6816e13ed9e7efb6f68ee9f5d4a1 doc_id: 721061 cord_uid: kaekj7ic Background Rapid diagnostics are vital for curving the transmission and control of COVID-19 pandemic. Although many commercially available antigen-based rapid diagnostic tests (Ag-RDTs) for the detection of SARS-CoV-2 are recommended by the WHO, their diagnostic performance has not yet been assessed in Ethiopia. So far, the vast majority of studies assessing diagnostic accuracies of rapid antigen tests considered RT-PCR as a gold standard, which inevitably leads to bias when RT-PCR is not 100% sensitive and specific. Thus, this study aimed to evaluate the diagnostic performance of Panbio COVID-19 rapid antigen test jointly together with the RT-PCR for the detection of SARS-CoV-2. Methods A prospective cross-sectional study was done from July to September 2021 in Addis Ababa, Ethiopia, during the third wave of the pandemic involving two health centers and two hospitals. Diagnostic sensitivity and specificity of Panbio rapid antigen test and RT-PCR were obtained using Bayesian Latent-Class Models (BLCM). Results 438 COVID-19 presumptive clients were enrolled, 239 (54.6%) were females, of whom 196 (44.7%) had a positive RT-PCR and 158 (36.1%) were Ag-RDT positive. The Ag-RDT and RT-PCR had a sensitivity (95% CrI) of 99.6 (98.4- 100), 89.3 (83.2- 97.6) and specificity (95% CrI) of 93.4 (82.3 - 100), 99.1 (97.5- 100) respectively. Most of the study participants, 318 (72.6) exhibited COVID-19 symptoms and the most reported was cough 191 (43.6). Conclusion The diagnostic performance of Panbio COVID-19 Ag RDT is coherent with the WHO established criteria of having a sensitivity [≥]80% for Ag-RDTs. Superior performance of the Panbio RDT was documented in samples with the lowest cycle-threshold RT-PCR values and clients with confirmed clinical symptoms. Thus, we recommend the use of the Panbio RDT for both symptomatic and asymptomatic individuals in clinical settings for screening purposes. The global public health and economic threats that resulted in countless disastrous effects 58 due to COVID-19 is being revealed in numerous ways and it's not yet over. More than 59 6,223,645 deaths from over 504,834,324 documented cases have been reported as of April 18, 60 2022, since its detection in December 2019 and its being declared as public health emergency 61 in March 2020 [1, 2, 3] . 62 In Africa, the current health systems and laboratory diagnostic capacities are at their 63 questionable with respect to managing outbreaks as early as possible. Accordingly, realizing The current choice of established tests for the diagnosis of COVID-19 with a relatively better 78 diagnostic performance using respiratory swab sample is RT-PCR, but its affordability and 79 infrastructure demand for most laboratories in the low-income countries are atypical. 80 Alternative testing modalities have become convenient approaches to reach more clients and 81 a step forward to empower individuals by bringing healthcare services closer to them. In view . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2022. ; https://doi.org/10.1101/2022.04.25.22274285 doi: medRxiv preprint of this, rapid antigen tests have been in place as an option with their comparable diagnostic 83 performance [9] [10] [11] . 84 The impact of rapid diagnostic testing (RDT) has been significant because results can be 85 delivered in short turnaround time of COVID-19 testing. RDT has become a game-changer for 86 triaging patients and crucial medical decisions [7, 12] . Compared to RDT, the procedure of RT-87 PCR is sophisticated, may lead to specimen contamination and technical personnel are prone The study population were all presumptive COVID-19 clients among public health facilities of 120 Addis Ababa who were willing to take part in the study and were available during data 121 collection period. We employed a convenience sampling technique until it reached a In this study, eligible participants from community surveillance, contacts of confirmed cases, 130 and suspects who fulfill the WHO criteria and Ethiopian guideline for COVID-19 cases were 131 screened by trained professionals as quick triage system [27] . Of these, a total of 438 132 nasopharyngeal swabs was collected by trained health professionals. 133 We excluded the critically ill cases, confirmed COVID-19 positive patients and with age ≤ 18 134 years old. Regarding test kit selection, Panbio™ COVID-19 Ag RDT was used for our study . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 28, 2022 138 We collected the nasopharyngeal respiratory specimens twice from each study participant 139 upon consent using viral transport medium: one for rapid antigen and the other for RT-PCR. The rapid Ag tests were analyzed immediately according to the manufacturers' instruction by is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 28, 2022 CoV-2 antigen (Ag) in a strictly safety percolations [28] . procedures, as part of assuring the quality management system, we always incorporate a 187 positive and negative quality controls. In addition, data were double entered to prevent error 188 during data entry via cross-checking and also finally checked and verified prior to analysis. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2022. (1,1)) were used for the sensitivities of both tests, the specificity of Panbio and the four 214 prevalences. The shape parameters for the specificity of the RT-PCR were obtained with beta 215 buster assuming "to be 95% sure that the specificity is greater than 90% with a mode at 99%" 216 as prior information. Convergence was assessed by visual inspection of the trace plots and . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2022. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2022. ; https://doi.org/10.1101/2022.04.25.22274285 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2022 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2022 The performance of Ag-RDT was also examined using different parameters or conditional 282 dependency, as depicted in table 3b and S1-S6 (supplementary files, S1-S6). Accordingly, rapid Ag-based diagnostic tests that could pinpoint patients at early disease 290 were commonly recommended. In this regard, the current status of our country's laboratory The diagnostic sensitivity and specificity of Panbio was comparable with reports by Nsoga et. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2022 in the specificity of the test performance among the negative cases, which may be due to the 304 difference in study participant recruitments, which is we used more the asymptomatic and A similar study conducted in Germany, Switzerland and Japan in comparing this RDT 324 diagnostic performance and using RT-PCR as a gold standard method of the classical method 325 model showed more comparable finding among symptomatic study participants and its . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2022 CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2022 388 We, the authors declare that they have no known competing financial interests or personal 389 relationships that could have appeared to influence the work reported in this paper . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2022 approval and their strong support and assistance in accessing diverse resources used in the 405 study. 406 We also acknowledge all the data collector and study participants. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 28, 2022 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 28, 2022. ; https://doi.org/10.1101/2022.04.25.22274285 doi: medRxiv preprint World Health Organization Best Practices for the Naming of New Human Infectious 413 A Novel Coronavirus from Patients with Pneumonia in 416 Rapid establishment of laboratory diagnostics for 420 the novel coronavirus SARS-CoV-2 in Bavaria Transforming our world: the 2030 Agenda for Sustainable Diagnostic Performance of SARS-CoV-2 IgM/IgG 428 Rapid Test Kits for the Detection of the Novel Coronavirus in Ethiopia Abbot global Point of Care Detection of SARS-CoV-2 434 infection by RT-PCR test: factors influencing interpretation of results. Virus disease Comparative analysis of various clinical specimens in detection of SARS-CoV-2 using 438 rRT-PCR in new and follow up cases of COVID-19 infection: Quest for the best choice Goudouris ES. Laboratory diagnosis of COVID-19 Performance of Seven Rapid Antigen Detection Kits for Detection of SARS-CoV-2 Virus Development of a Laboratory-safe and Low-cost Detection 446 Protocol for SARS-CoV-2 of the Coronavirus Disease 2019 (COVID-19) Point-of-Care RNA-Based Diagnostic Device for 449 COVID-19. Diagnostics Rapid Antigen Test Kits for Detecting SARS-CoV-2: A Systematic Review and Meta-452 Analysis of 17,171 Suspected COVID-19 Patients Diagnostic accuracy of 457 three commercially available one step RT-PCR assays for the detection of SARS-CoV-2 458 in resource limited settings Analysis of factors associated with disease outcomes in 461 hospitalized patients with 2019 novel coronavirus disease Molecular and serological investigation of 2019-nCoV 464 infected patients: implication of multiple shedding routes Chinese expert consensus on the perinatal and neonatal 467 management for the prevention and control of the 2019 novel coronavirus infection Diagnostic accuracy of Panbio rapid antigen tests on oropharyngeal 471 swabs for detection of SARS-CoV-2 Clinical performance evaluation of 474 SARS-CoV-2 rapid antigen testing in point of care usage in comparison to RT-qPCR Field evaluation of a rapid antigen test COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres Evaluation of Panbio 480 rapid antigen test for SARS-CoV-2 in symptomatic patients and their contacts: a 481 multicenter study World Health Organization (WHO). COVID-19 Preparedness Bulletin Ethiopia Laboratory testing for coronavirus disease (COVID-19) in suspected human 489 cases: interim guidance COVID-19 Ag Rapid Test Device (Nasopharyngeal) Accessed date March 12, 2022. 497 29. Manufacturer's Instructions for Use gb/panbio/120007883-v1-Panbio-COVID-19-Ag-Nasal-AsymptomaticSe.pdf. Accessed 499 date Real-time fluorescent RT-PCR kit for 501 detecting 2019-nCoV East Lake High-503 tech Development Zone, Wuhan 504 31. Cohen's kappa Kappa value interpretation (see Landis runjags: An R Package Providing Interface Utilities Model Templates, Parallel Computing Methods and Additional Distributions for MCMC 509 R: A language and environment for statistical computing. R 511 Foundation for Statistical Computing DescTools: Tools for descriptive statistics Evaluation of a rapid antigen test 544 (Panbio™ COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic 545 close contacts of COVID-19 patients Assessment of 12 qualitative RT-PCR 548 commercial kits for the detection of SARS-CoV-2 Supplementary materials R 553 S2: performance analysis with weakly informative priors 554 S3: Graphical output from the final BLCM (trace plot, ECDF, density and autocorrelation plot) 555 for sensitivity of Panbio rapid antigen test 556 S4: Graphical output from the final BLCM (trace plot, ECDF, density and autocorrelation plot) 557 for sensitivity of RT-PCR S5: Graphical output from the final BLCM (trace plot, ECDF, density and autocorrelation plot) 559 for specificity of Panbio rapid antigen test 560 S6: Graphical output from the final BLCM